Literature DB >> 17470396

Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.

M Mpandi1, P Schmutz, E Legrand, R Duc, J Geinoz, C Henzelin-Nkubana, S Giorgia, O Clerc, D Genoud, T Weber.   

Abstract

Caprylic acid (octanoic acid), has been used for over 50 years as a stabilizer of human albumin during pasteurization. In addition caprylic acid is of great interest, by providing the advantage of purifying mammalian immunoglobulins and clearing viruses infectivity in a single step. Exploiting these two properties, we sequentially used the caprylic acid precipitation and the pasteurization to purify horse hyperimmune globulins used in the manufacturing of Sérocytol. To evaluate the effectiveness of the process for the removal/inactivation of viruses, spiking studies were carried out for each dedicated step. Bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), encephalomyocarditis virus (EMCV) and minute virus of mice (MVM) were used for the virological validation. Our data show that the treatment with caprylic acid 5% (v/v) can effectively be used as well to purify or to ensure viral safety of immunoglobulins. Caprylic acid precipitation was very efficient in removing and/or inactivating enveloped viruses (PRV, BVDV) and moderately efficient against non-enveloped viruses (MVM, ECMV). However the combination with the pasteurization ensured an efficient protection against both enveloped and non-enveloped viruses. So that viruses surviving to the caprylic acid precipitation will be neutralized by pasteurization. Significant log reduction were achieved > or =9 log(10) for enveloped viruses and 4 log(10) for non-enveloped viruses, providing the evidence of a margin of viral safety achieved by our manufacturing process. Its a simple and non-expensive manufacturing process of immunoglobulins easily validated that we have adapted to a large production scale with a programmable operating system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470396     DOI: 10.1016/j.biologicals.2007.02.004

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.

Authors:  Guillermo León; María Herrera; Mariángela Vargas; Mauricio Arguedas; Andrés Sánchez; Álvaro Segura; Aarón Gómez; Gabriela Solano; Eugenia Corrales-Aguilar; Kenneth Risner; Aarthi Narayanan; Charles Bailey; Mauren Villalta; Andrés Hernández; Adriana Sánchez; Daniel Cordero; Daniela Solano; Gina Durán; Eduardo Segura; Maykel Cerdas; Deibid Umaña; Edwin Moscoso; Ricardo Estrada; Jairo Gutiérrez; Marcos Méndez; Ana Cecilia Castillo; Laura Sánchez; Ronald Sánchez; José María Gutiérrez; Cecilia Díaz; Alberto Alape
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

2.  Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries.

Authors:  Magdy El-Ekiaby; Mariángela Vargas; Makram Sayed; George Gorgy; Hadi Goubran; Mirjana Radosevic; Thierry Burnouf
Journal:  PLoS Negl Trop Dis       Date:  2015-02-26

3.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27

4.  Back to the Cradle of Cytotherapy: Integrating a Century of Clinical Research and Biotechnology-Based Manufacturing for Modern Tissue-Specific Cellular Treatments in Switzerland.

Authors:  Alexis Laurent; Philippe Abdel-Sayed; Corinne Scaletta; Philippe Laurent; Elénie Laurent; Murielle Michetti; Anthony de Buys Roessingh; Wassim Raffoul; Nathalie Hirt-Burri; Lee Ann Applegate
Journal:  Bioengineering (Basel)       Date:  2021-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.